# EDGAR Filing Document

**Accession Number:** 0001485003
**File Stem:** 0000894579-23-000135
**Filing Date:** 2023-3
**Character Count:** 9617
**Document Hash:** 6c5d249e4e80bb19b35ce32ad4cf4708
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000894579-23-000135.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0000894579-23-000135

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Carisma Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001485003
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 262025616
- **STATE OF INCORPORATION:** PA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87951
- **FILM NUMBER:** 23728188

**BUSINESS ADDRESS:**
- **STREET 1:** 3675 MARKET STREET
- **STREET 2:** SUITE 200
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104
- **BUSINESS PHONE:** 2674916422

**MAIL ADDRESS:**
- **STREET 1:** 3675 MARKET STREET
- **STREET 2:** SUITE 200
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sesen Bio, Inc.
- **DATE OF NAME CHANGE:** 20180516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eleven Biotherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20100223
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ModernaTX, Inc.
- **CENTRAL INDEX KEY:** 0001962626
- **IRS NUMBER:** 270226313
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 200 TECHNOLOGY SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-800-4592

**MAIL ADDRESS:**
- **STREET 1:** 200 TECHNOLOGY SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

------

**UNITED STATES**

<br> ### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549
**SCHEDULE 13G** <br>

**Under the Securities Exchange Act of 1934**

<br> **(Amendment No.)\***<br>

---

| |
|:---|
| **CARISMA THERAPEUTICS INC.**<br>|
| (Name of Issuer) |
| **Common Stock, par value $0.001 per share**<br>|
| (Title of Class of Securities) |
| **817763105** <br>|
| (CUSIP Number) |
| **March 7, 2023**<br>|
| (Date of Event Which Requires Filing of this Statement) |

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

---

| | | |
|:---|:---|:---|
| **1** | **NAME OF REPORTING PERSONS:** | **NAME OF REPORTING PERSONS:** |
| **1** | ModernaTX, Inc. | ModernaTX, Inc. |
| **1** | ModernaTX, Inc. | ModernaTX, Inc. |
| **2** | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:** | **CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:** |
| **2** | (a)☐ | (a)☐ |
| **2** | (b)☒ | (b)☒ |
| **3** | **SEC USE ONLY** | **SEC USE ONLY** |
| **3** |  |  |
| **3** |  |  |
| **4** | **CITIZENSHIP OR PLACE OF ORGANIZATION:** | **CITIZENSHIP OR PLACE OF ORGANIZATION:** |
| **4** | Delaware | Delaware |
| **4** | Delaware | Delaware |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **5** | **SOLE VOTING POWER:** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **5** | 5059338 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **5** | 5059338 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **6** | **SHARED VOTING POWER:** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **6** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **6** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **7** | **SOLE DISPOSITIVE POWER:** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **7** | 5059338 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **7** | 5059338 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **8** | **SHARED DISPOSITIVE POWER:** |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **8** | 0 |
| **NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH** | **8** | 0 |
| **9** | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:** | **AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:** |
| **9** | 5059338 | 5059338 |
| **9** | 5059338 | 5059338 |
| **10** | **CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)** | **CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)** |
| **10** | ☐ | ☐ |
| **10** | ☐ | ☐ |
| **11** | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):** | **PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):** |
| **11** | 12.57%(1) | 12.57%(1) |
| **11** | 12.57%(1) | 12.57%(1) |
| **12** | **TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):** | **TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):** |
| **12** | CO | CO |
| **12** | CO | CO |

---

(1) Percentage calculated based upon 40,254,666 shares of Common Stock outstanding as of March 7, 2023, based on information obtained from the Issuer.

------

**Item 1(a). Name of Issuer:

#### CARISMA THERAPEUTICS INC. <br>
Item 1(b). Address of Issuer's Principal Executive Offices:

245 First Street, Suite 1800<br>

Cambridge, MA 02142<br>

Item 2(a). Name of Person Filing:

ModernaTX, Inc.<br>

Item 2(b). Address of Principal Business Office or, if none, Residence:

c/o Moderna, Inc.<br>

200 Technology Square<br> Cambridge, MA 02139<br>

617-714-6500<br>

Item 2(c). Citizenship:

Delaware

Item 2(d). Title of Class of Securities:

#### Common Stock, par value $0.001 per share<br>
Item 2(e). CUSIP Number:

817763105** 

**Item 3.** **If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or**

#### 240.13d-2(b) or (c):

#### <br>

#### Not applicable

#### <br>

------

**Item 4. Ownership.

(a) Amount beneficially owned:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,059,338<br>

(b) Percent of class: 12.57%(1)

<br> (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,059,338<br>

(ii) Shared power to vote or to direct the vote:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Sole power to dispose or to direct the disposition of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,059,338<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Shared power to dispose or to direct the disposition of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0**

**Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.<br>

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not Applicable.<br>

Item 8. Identification and Classification of Members of the Group.

Not Applicable.<br>

Item 9. Notice of Dissolution of Group.

Not Applicable.**

<br> **Item 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

(1) Percentage calculated based upon 40,254,666 shares of Common Stock outstanding as of March 7, 2023, based on information obtained from the Issuer.

------

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 13, 2023<br>

---

| | |
|:---|:---|
| ModernaTX, Inc. | ModernaTX, Inc. |
| By: | /s/Brian Sandstrom<br>|
|  | Name: Brian Sandstrom<br>|
|  | Title: Assistant Secretary<br>|

---

------